Concepedia

Renee Ward

RW

11

Publications

581

Citations

10

H-Index

2007

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Memorial Sloan Kettering Cancer Center

Moffitt Cancer Center

Cornell University

Sunesis (United States)

Renee Ward is an author at The University of Texas MD Anderson Cancer Center specializing in pharmacotherapy, medicine, and pharmacology.

Top concepts

Publications per year

2007–2021

11

Publications

11

Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia

Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle et al. · Journal of Clinical Oncology · 2011 · 247 citations · Full text

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Farhad Ravandi, Ellen K. Ritchie, Hamid Sayar et al. · The Lancet Oncology · 2015 · 153 citations · Full text

, , +8

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

John N. Allan, Javier Pinilla‐Ibarz, Douglas E. Gladstone et al. · Haematologica · 2021 · 35 citations · Full text

, , +14

First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects

Linda Neuman, Renee Ward, David Arnold et al. · Blood · 2016 · 30 citations

Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies

John N. Allan, Krish Patel, Anthony R. Mato et al. · Blood · 2019 · 28 citations

Rows per page

1–5 of 11